Mansoor Raza Mirza, MD, discusses the evolving treatment landscape in recurrent ovarian cancer.
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses the evolving treatment landscape in recurrent ovarian cancer.
Over the past 5 years, there have been several breakthroughs in the ovarian cancer treatment landscape, says Mirza. Reflecting back on past studies, the ENGOT-OV16/NOVA trial, which was presented in 2016, was the first randomized phase 3 study to assess the utility of PARP inhibitors in this space.
In the trial, patients with platinum-sensitive recurrent ovarian cancer were randomized 2:1 to receive maintenance therapy with niraparib versus placebo.
Ultimately, by incorporating niraparib (Zejula) into the treatment paradigm, this study transformed the treatment landscape in both Europe and the United States.